Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $10.00

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been given an average recommendation of “Hold” by the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $10.00.

A number of analysts recently commented on REPL shares. Piper Sandler increased their target price on shares of Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Wedbush lifted their price target on shares of Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th.

Institutional Investors Weigh In On Replimune Group

Institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Replimune Group by 17.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after purchasing an additional 6,653 shares during the last quarter. Millennium Management LLC boosted its position in shares of Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after purchasing an additional 33,574 shares during the period. Goldman Sachs Group Inc. increased its stake in Replimune Group by 20.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after purchasing an additional 119,145 shares in the last quarter. Rhumbline Advisers increased its stake in Replimune Group by 6.9% in the 2nd quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after purchasing an additional 6,616 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Replimune Group during the 2nd quarter worth about $583,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Price Performance

NASDAQ:REPL opened at $7.65 on Friday. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. The business’s 50-day moving average price is $7.56 and its 200 day moving average price is $7.80. Replimune Group has a 52-week low of $2.68 and a 52-week high of $13.24. The firm has a market cap of $631.66 million, a P/E ratio of -2.22 and a beta of 0.72.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.08. As a group, sell-side analysts predict that Replimune Group will post -2.97 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.